Wikipedia
Atezolizumab
Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). It is currently in clinical trials as an immunotherapy for several types of solid tumors. It is under investigation by Genentech/ Roche.
In April 2016 Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA.
In May 2016 it was approved by the FDA for bladder cancer treatment.